Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 69Carcinoma, Intraductal, Noninfiltrating 9Breast Carcinoma In Situ 6Breast Neoplasms, Male 5Neoplasms 3Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Inflammatory Breast Neoplasms 2Sleep Wake Disorders 1Risk Reduction Behavior 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Obesity 1Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer 1Mastodynia 1Glioma 1Fibrocystic Breast Disease 1Fibroadenoma 1Fatigue 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Disease Progression 1Desmoid Tumors 1Cystic Fibrosis 1Cystadenocarcinoma, Serous 1Carcinoma, Ovarian Epithelial 1Carcinoma, Lobular 1Bulbo-Spinal Atrophy, X-Linked 1Breast Cancer Metastatic 1

Interventions

Paclitaxel 2Letrozole 2trametinib 1ribociclib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1Axitinib 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cystadenocarcinoma, Serous × Tamoxifen × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡